Mechanisms of antiaddictive actions of ibogaine

Glick and colleagues introduce ibogaine, an indole alkaloid from Tabernanthe iboga, as a candidate long‑acting treatment for several substance use disorders, including opioid and stimulant dependence, alcoholism and nicotine dependence. They note that ibogaine and its active metabolite noribogaine act at multiple neural targets, and argue that such a pleiotropic pharmacology may underlie any broad antiaddictive efficacy; the paper therefore sets out to characterise ibogaine's behavioural effects in animal models and to probe the receptor and neurotransmitter mechanisms responsible. The study uses rodent models of drug self‑administration, locomotor activity and in vivo microdialysis to examine acute and longer‑lasting effects of ibogaine and noribogaine on drug intake, dopamine and serotonin transmission, and related behaviours. The investigators aim to determine which receptor interactions—kappa opioid, NMDA (N‑methyl‑D‑aspartate), serotonin transporter, nicotinic and sigma‑2 among others—contribute to ibogaine's antiaddictive and adverse effects, and to consider metabolic and pharmacokinetic factors that could account for durable outcomes.

Subjects were drug‑naive female Sprague–Dawley or Long–Evans rats (approximately 3 months old, 230–250 g) maintained on a standard 12:12 light/dark cycle. Experimental methods comprised intravenous self‑administration for morphine and cocaine, an oral operant model for nicotine preference, locomotor activity monitoring, and in vivo microdialysis to measure extracellular monoamines. For intravenous self‑administration, rats were trained to press levers for water, then implanted with external jugular cannulae. Testing began with a 16‑hr nocturnal session followed by daily 1‑hr sessions (Monday–Friday). Each lever press produced an infusion of drug solution (text reports per‑infusion amounts of 0.01 mg morphine sulfate or 0.1 mg cocaine hydrochloride; because body weights were ~250 ± 20 g, the authors estimate each response delivered roughly 0.04 mg/kg morphine or 0.4 mg/kg cocaine). Nicotine self‑administration used an oral two‑lever procedure in which presses on one lever delivered nicotine solution and presses on the other delivered water; rats were water‑restricted to motivate responding and nicotine introduction followed stable water‑responding. Locomotor activity was recorded in cylindrical photocell cages that registered beam interruptions. For in vivo microdialysis, stereotaxic guide cannulae targeted nucleus accumbens, striatum or medial prefrontal cortex; CMA probes (2–3 mm) were perfused at 1 µl/min with physiological saline and 20‑minute fractions collected. Dialysates were analysed by HPLC with electrochemical detection to quantify dopamine, serotonin and relevant metabolites. Where reported, pharmacological probes included kappa opioid agonists (U50,488, spiradoline), a kappa antagonist (norbinaltorphimine; norBNI), an NMDA antagonist (MK‑801) and exogenous NMDA to counter NMDA blockade. Doses and timing used in key experiments include ibogaine 40 mg/kg i.p., with acute testing at 15 minutes and pretreatment regimens often 19 hours prior to challenge.

Ibogaine reduced operant self‑administration of both morphine and cocaine in rats. When given 40 mg/kg i.p. 15 minutes before testing on Day 1, ibogaine decreased responding for both drugs; the authors caution that Day 1 effects may be confounded by transient motor disturbance, but significant reductions on Day 2 occurred when motor behaviour appeared normal. Approximately 35% of rats showed prolonged suppression of morphine or cocaine intake for several days to as long as three weeks after a single ibogaine administration. Effects on orally self‑administered nicotine were shorter lived: ibogaine pretreatment blocked nicotine‑induced nucleus accumbens dopamine release and reduced nicotine preference on Day 2 without altering overall response rates for water or nicotine at that time. Mechanistic pharmacology data implicated multiple receptor systems. A combined pretreatment with the kappa opioid antagonist norBNI and exogenous NMDA (used as an NMDA agonist) significantly antagonised several ibogaine effects (for example, decreases in morphine self‑administration, inhibition of morphine‑induced locomotor stimulation when ibogaine was given 19 hours earlier, and inhibition of striatal dopamine release), whereas norBNI or NMDA alone did not. Complementary experiments showed that kappa agonists (U50,488; spiradoline) and the NMDA antagonist MK‑801 mimic some ibogaine actions: both classes attenuated morphine‑induced locomotor stimulation, and kappa agonists reduced both morphine and cocaine self‑administration. By contrast, MK‑801 reduced morphine self‑administration but did not consistently suppress cocaine self‑administration. Serotonergic and nicotinic interactions were also reported. Noribogaine displayed about tenfold higher affinity for the serotonin transporter than ibogaine and was more potent in elevating extracellular serotonin in nucleus accumbens, although the extracted text indicates ibogaine may be more efficacious as a serotonin releaser. The authors link serotonergic effects to transient reductions in alcohol intake and to early subjective/hallucinogenic effects. High‑dose ibogaine (reported at 100 mg/kg) produced cerebellar Purkinje cell damage in rats, but damage was dose‑dependent and species‑specific: 40 mg/kg produced no detectable cerebellar lesion in some studies, and mice were resistant at doses that were neurotoxic in rats. In vitro and structure–activity work implicated sigma‑2 receptors in ibogaine's neurotoxicity. A synthetic congener, 18‑methoxycoronaridine (18‑MC), reproduced ibogaine's suppression of morphine and cocaine self‑administration without producing cerebellar toxicity and showed low sigma‑2 affinity. Pharmacokinetic and metabolic observations indicate that ibogaine is sequestered in fat and possibly other tissues (platelets were mentioned), and is metabolised to noribogaine. Noribogaine and tissue sequestration may contribute to prolonged behavioural effects; variability in effects between animals and humans may reflect differences in fat deposition and metabolic conversion. The extracted text does not clearly report full quantitative plasma and brain concentration–time data for noribogaine across studies.

Glick and colleagues interpret their findings as supporting a multi‑target mechanism for ibogaine's antiaddictive actions. They argue that, unlike traditional single‑target pharmacotherapies or pharmacokinetic replacements, an agent with several complementary receptor actions may be needed to attenuate the diverse neurobiological processes underlying different substance use disorders. The authors suggest that combined kappa opioid agonism, NMDA antagonism and nicotinic antagonism could together dampen mesolimbic dopamine system responsivity to addictive drugs, while serotonergic effects may account for short‑lived reductions in alcohol intake and some acute subjective effects. The paper also addresses earlier concerns about neurotoxicity. The investigators consider initial reports of ibogaine‑induced cerebellar Purkinje cell damage to have provoked excessive caution, noting that toxicity is dose dependent and species specific, and pointing to more recent data and the development of less neurotoxic congeners (for example 18‑MC) as reasons to continue preclinical and clinical evaluation. Mechanistically, they propose that sigma‑2 receptor agonism may mediate neurotoxicity, possibly via glutamate release in the cerebellum, which could reconcile the paradox that ibogaine both antagonises NMDA receptors and yet produces glutamate‑linked toxicity at high doses. Finally, the authors discuss pharmacokinetic contributors to long‑term effects, emphasising fat sequestration and metabolism to noribogaine as plausible explanations for prolonged behavioural outcomes and for intersubject variability. They conclude that ibogaine's complex pharmacology merits further study and that ibogaine should be viewed as a prototype for a novel class of antiaddictive agents, while noting that refinement to reduce toxicity appears feasible. The authors acknowledge variability and incomplete understanding in some receptor interactions (for example serotonergic binding inconsistencies reported in the literature), and they frame future work as necessary to clarify mechanisms and therapeutic potential.